Neogenomics Inc (NASDAQ: NEO) kicked off on Friday, up 3.02% from the previous trading day, before settling in for the closing price of $13.59. Over the past 52 weeks, NEO has traded in a range of $12.77-$21.22.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 17.35% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded 152.34%. With a float of $126.56 million, this company’s outstanding shares have now reached $127.37 million.
In an organization with 2100 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 41.54%, operating margin of -14.54%, and the pretax margin is -13.28%.
Neogenomics Inc (NEO) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Diagnostics & Research Industry. The insider ownership of Neogenomics Inc is 1.24%, while institutional ownership is 98.41%. The most recent insider transaction that took place on Aug 15 ’24, was worth 16,695. In this transaction General Counsel of this company sold 1,040 shares at a rate of $16.05, taking the stock ownership to the 43,813 shares. Before that another transaction happened on Aug 15 ’24, when Company’s Officer proposed sale 1,040 for $15.82, making the entire transaction worth $16,453.
Neogenomics Inc (NEO) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 152.34% per share during the next fiscal year.
Neogenomics Inc (NASDAQ: NEO) Trading Performance Indicators
Take a look at Neogenomics Inc’s (NEO) current performance indicators. Last quarter, stock had a quick ratio of 1.93. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.94.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.62, a number that is poised to hit 0.01 in the next quarter and is forecasted to reach 0.20 in one year’s time.
Technical Analysis of Neogenomics Inc (NEO)
Let’s dig in a bit further. During the last 5-days, its volume was 0.61 million. That was inferior than the volume of 0.81 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 73.82%. Additionally, its Average True Range was 0.50.
During the past 100 days, Neogenomics Inc’s (NEO) raw stochastic average was set at 22.32%, which indicates a significant decrease from 77.70% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 27.39% in the past 14 days, which was lower than the 49.46% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $14.80, while its 200-day Moving Average is $14.86. However, in the short run, Neogenomics Inc’s stock first resistance to watch stands at $14.33. Second resistance stands at $14.67. The third major resistance level sits at $15.00. If the price goes on to break the first support level at $13.66, it is likely to go to the next support level at $13.33. The third support level lies at $12.99 if the price breaches the second support level.
Neogenomics Inc (NASDAQ: NEO) Key Stats
The company with the Market Capitalisation of 1.85 billion has total of 128,158K Shares Outstanding. Its annual sales at the moment are 591,640 K in contrast with the sum of -87,970 K annual income. Company’s last quarter sales were recorded 164,500 K and last quarter income was -18,640 K.
